China’s National Health Commission (NHC) issued the Working Procedures for Formulating the Rare Disease Catalogue (2026 Edition) on 4 Nov 2026, a policy revision designed to strengthen rare disease management, enhance the scientific rigor and rationality of catalogue drafting, and reinforce national standards for rare disease diagnosis, treatment, and coverage.
Policy Snapshot
| Item | Detail |
|---|---|
| Issuing Authority | National Health Commission (NHC), with the National Administration of Traditional Chinese Medicine (NATCM) added as co‑issuing authority |
| Document | Working Procedures for Formulating the Rare Disease Catalogue (2026 Edition) |
| Issue Date | 4 Nov 2026 |
| Objective | Strengthen rare disease management; improve scientific rigor of catalogue drafting; reinforce diagnosis, treatment, and coverage standards nationwide |
| Key Changes | Expanded inclusion criteria; broadened eligible applicants; NATCM co‑issuance; optimized update cycle; clarified catalogue’s reference role |
Expanded Inclusion Criteria
The revision expands the conditions eligible for inclusion, broadening the scope of covered diseases. Under the new procedures, diseases included in the catalogue must concurrently meet the following core criteria – with newly introduced alternative pathways:
- ① Epidemiological Evidence: International and domestic evidence demonstrates a low incidence or prevalence rate.
- ② Disease Burden: The condition poses significant harm to patients and their families.
- ③ Diagnosability: Clear diagnostic methods are available.
- ④ Actionability – Three Qualifying Routes:
- Effective treatment or intervention modalities exist; OR
- Where effective treatments are not yet available, the condition has been included in national key research initiatives; OR
- The condition holds high value for preventive screening and scientific research.
The second and third routes mark a notable policy shift: untreatable rare diseases can now qualify on the strength of national research priority status or screening/scientific value alone – opening the catalogue to conditions previously excluded for lack of therapy.
Procedural Reforms
- Broader Applicant Pool: The procedures expand the entities eligible to apply for disease inclusion, fully leveraging the role of relevant specialized institutions beyond the traditional application channels.
- TCM Integration: The NATCM’s addition as a co‑issuing authority clarifies Traditional Chinese Medicine regulatory responsibilities and promotes TCM–Western medicine integration in rare disease prevention and treatment.
- Faster Updates: The catalogue update cycle is optimized to allow timely, practical updates – moving away from the multi‑year revision intervals that characterized earlier editions.
- Institutional Authority: The procedures clarify that the catalogue serves as a key reference for relevant authorities in their respective duties, anchoring its role across pricing, reimbursement, and approval policy.
Market Impact & Outlook
- Access Catalyst: Inclusion in the NHC rare disease catalogue has historically functioned as a gateway to priority review, reimbursement negotiation leverage, and hospital procurement support – a broader, faster‑updating catalogue expands these benefits to more conditions and more patients.
- Pharma Strategy Signal: For global and domestic rare‑disease developers, the inclusion of research‑stage and untreatable conditions suggests China is aligning catalogue membership with national R&D priorities, potentially rewarding early investment in locally relevant orphan indications.
- Screening & Diagnostics Opportunity: The preventive screening and scientific research route creates policy tailwinds for genetic testing, newborn screening, and diagnostic companies targeting rare disease detection.
- TCM Sector Inclusion: NATCM co‑issuance formally integrates Traditional Chinese Medicine into rare disease governance – a first that may influence treatment standards and coverage for TCM‑relevant rare conditions.
- Next Steps: Timing of the next full catalogue edition under the new procedures and the number of conditions added were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding implementation of the Working Procedures for Formulating the Rare Disease Catalogue (2026 Edition), future catalogue updates, and their potential effects on rare disease diagnosis, treatment, coverage, and market access in China. Actual outcomes may differ due to administrative processes, disease‑inclusion decisions, reimbursement policy changes, and stakeholder participation.-Fineline Info & Tech
